However, a clinical phase I trial of polatuzumab vedotin, an anti-Igβ antibody fused to a microtubule-disrupting drug named monomethyl auristatin E, did not show any clinical responses in CLL (50). Here, CD79B is linked to B-cell chronic lymphocytic leukemia.